Generation Bio

United States
Primghar, Iowa, United States, MA 02142

Company profile

Generation Bio company profile

Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2016-01-01, Year

Headquarters

Postal code
MA 02142
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
5
Total equity funding
$536.4M
Last funding
Post IPO Equity / $76M / 2023-03-23
Last equity funding
Post IPO Equity / $76M
Investors
11
Lead investors
4
Founders
4
Articles
114
Exited on
2020-06-11

Founders and investors

Founders

Andrew ScharenbergMark D. AngelinoPhillip SamayoaRobert Kotin

Lead investors

Atlas VentureFidelityModernaT. Rowe Price

Investors

Casdin CapitalFidelityForesite CapitalModernaWellington Management